Home > Boards > US Listed > Biotechs > BioVie Inc. (BIVI)

New Delivery System Designed to Enable Home Care Therapy

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ejobkar Member Profile
 
Followed By 3
Posts 852
Boards Moderated 0
Alias Born 03/05/12
160x600 placeholder
ejobkar   Monday, 12/09/19 10:04:06 PM
Re: None
Post # of 759 
New Delivery System Designed to Enable Home Care Therapy

"BioVie’s new patent-pending formulation of terlipressin has demonstrated the potential for room-temperature storage. If extended room-temperature product stability can be shown, this feature could provide another key product advantage. To the best of the Company’s knowledge, all other terlipressin products sold globally must be stored under refrigeration and there are no prefilled syringe formats available for treating patients."

"In addition, the Company has a pending patent application covering the proprietary liquid formulation of terlipressin to be used in its planned Phase 2b/3 trial, subject to FDA clearance. This could eventually provide up to 20 years of patent coverage in each country for which the Company seeks patent protection, including the US, according to the patent laws of that country."

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences